First Use of Control-IQ+ Technology in Newly Indicated Populations

Abstract

Background:

Control-IQ+ technology (Control-IQ+) is available to Tandem t:slim X2 and Tandem Mobi insulin pump users in the United States. This algorithm update enhances support for individuals with a broader range of insulin needs and offers additional new features: extended bolus and temp basal rates during automation. This study aimed to describe early real-world use of Control-IQ+ in newly indicated populations.

Methods:

Data from users of Control-IQ+ (t:slim X2 or Tandem Mobi) with ≥14 days and ≥70% continuous glucose monitoring availability in the Tandem Source web application from March 2025 to June 2025 were retrospectively analyzed. Results were stratified according to total daily insulin (TDI) use: <10 units/day (low), 10–100 units/day (moderate), or >100 units/day (high).

Results:

A total of 40,320 Control-IQ+ users met criteria for analysis (51.7% female, median age 45.6 years, 92.8% type 1 diabetes), with 451 (1%) classified as low TDI, 38,259 (95%) classified as moderate TDI, and 1610 (4%) classified as high TDI. Median percent time in automation was >90% across all subgroups. Median time in range (TIR) for the overall cohort was 71.4%, with similar values observed in low (72.7%) and moderate (71.7%) TDI users. Hypoglycemia rates were low across all groups regardless of TDI. Proactive advanced features such as extended bolus and temp basal were utilized by the minority of the cohort, with the low-TDI group using these features the most (12.2% using temp basal and 26.4% using extended bolus).

Conclusions:

In this first report, Control-IQ+ users experience high time in automation, and those with low and moderate insulin needs exceeded consensus glycemic goals. The majority of users do not use the advanced features routinely, indicating proactive engagement may be useful but is not necessary with Control-IQ+.